OncoMatch/Clinical Trials/NCT06069726
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Is NCT06069726 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Atezolizumab for recurrent glioblastoma.
Treatment: Atezolizumab — This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Prior therapy
Must have received: radiation therapy
Clinical or radiologic evidence of first or second recurrence following radiation and TMZ
Must have received: temozolomide (temozolomide)
Clinical or radiologic evidence of first or second recurrence following radiation and TMZ
Cannot have received: immunotherapy
Prior treatment with immunotherapy
Cannot have received: bevacizumab (bevacizumab)
Exception: permitted if necessary to control inflammatory side effects 5-7mg/kg Q 3/52 for up to 3 cycles
Prior treatment with bevacizumab within 4 weeks before biopsy
Cannot have received: CD137 agonist
Prior treatment with CD137 agonists
Cannot have received: immune checkpoint blockade therapy
Prior treatment with immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
Cannot have received: investigational therapy
Treatment with investigational therapy within 28 days prior to initiation of study treatment
Cannot have received: allogeneic stem cell or solid organ transplantation
Prior allogeneic stem cell or solid organ transplantation
Lab requirements
Blood counts
Hemoglobin ≥ 9 g/dl; Platelet count ≥ 75,000/µl; Neutrophil count ≥ 1000 cells/mm3; Prothrombin and Partial Thromboplastin Times ≤ 1.2 x ULN
Kidney function
Creatinine ≤ 1.5 x ULN (Cockcroft-Gault formula)
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 3.0 x ULN if Gilbert's Syndrome); ALP ≤ 2.5 x ULN; AST and ALT ≤ 2.5 x ULN; Serum albumin ≥ 25 g/L (2.5 g/dL)
Adequate organ function: Hemoglobin ≥ 9 g/dl; Platelet count ≥ 75,000/µl; Neutrophil count ≥ 1000 cells/mm3; Creatinine ≤ 1.5 x ULN; Total bilirubin ≤ 1.5 x ULN (≤ 3.0 x ULN if Gilbert's Syndrome); ALP ≤ 2.5 x ULN; AST and ALT ≤ 2.5 x ULN; Serum albumin ≥ 25 g/L (2.5 g/dL); Prothrombin and Partial Thromboplastin Times ≤ 1.2 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
- Saint Luke's Cancer Institute · Kansas City, Missouri
- Duke University · Durham, North Carolina
- Huntsman Cancer Institute · Salt Lake City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06069726 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunotherapy, bevacizumab, CD137 agonist disqualifies patients from enrollment.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages